Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum apoprotein A-I and A-II levels were determined by electroimmunoassay in patients with liver diseases and cholestasis. Significant decreases in apoprotein A-I and A-II levels were observed in such patients. The decreases were especially pronounced in the early phase of acute hepatitis and cholestasis. The decreases in A-II levels were more prominent than the decreases in A-I in severe hepatic dysfunction or cholestasis. Accordingly, the A-I/A-II ratio showed no change in the convalescent phase of acute hepatitis or chronic hepatitis but increased significantly in the early phase of acute hepatitis, cirrhosis of the liver, hepatoma, and cholestasis. The results suggested the existence of a high density lipoprotein with an abnormal apoprotein composition or a more profound decrease of HDL3 than of HDL2 in severe hepatocellular dysfunction of cholestasis.
 ...
PMID:Serum apoprotein A-I and A-II levels in liver diseases and cholestasis. 627 23

To elucidate the role of the liver in the metabolism of HDL subfractions, the levels of HDL2 and HDL3 were determined in the sera obtained from patients with liver disease. The determinations were carried out either by zonal ultracentrifugation or by gradient gel electrophoresis combined with HDL cholesterol measurement. Mean HDL3 cholesterol level in patients with liver cirrhosis was about one third of the normal controls whereas no significant changes were observed in HDL2 cholesterol concentration. HDL3 cholesterol levels in patients with chronic hepatitis were about a half of the controls. The levels of HDL3 cholesterol correlated significantly to the levels of serum albumin and to choline esterase activities. The results suggest either that HDL3 is synthesized in the liver or that there is a metabolic defect in the conversion of HDL2 to HDL3 in liver disease.
 ...
PMID:Quantitative determinations of HDL2 and HDL3 in patients with liver disease. 683 48

In order to further investigate plasma lipoproteins abnormalities secondary to serious liver damage, we studied plasma lipids and lipoproteins, and in particular HDL subfractions (HDL2, HDL3), in 12 patients with cirrhosis of the liver and in 12 sex, age and weight matched healthy volunteers. Enzymatic methods were used to determine total cholesterol and triglycerides, while the extractive method of Abell et al. was used for the determination of HDL-cholesterol levels after LDL and VLDL precipitation with polyanions (MnCl2 and Na-heparin) and of HDL3-cholesterol values after HDL2 precipitation with dextran-sulphate 15,000 m.w. Total cholesterol and HDL-cholesterol levels were significantly lower in cirrhotic patients compared to normal subjects. We must emphasize that only HDL3-cholesterol was decreased in cirrhotics, whereas HDL2-cholesterol values were normal or high. We suggest that a diminished activity of hepatic triglyceride lipase might account for the decrease in HDL3-cholesterol in liver cirrhosis.
 ...
PMID:[HDL2 and HDL3 cholesterol in hepatic cirrhosis]. 686 Apr 95

In order to study the role and metabolism of high density lipoprotein (HDL) subfractions, the serum HDL2-cholesterol (HDL2-C) and HDL3-cholesterol (HDL3-C) were measured by the new method using high performance liquid chromatography in the normal subjects and patients with various diseases. It was highly characteristic that the serum HDL3-C levels of the patients with liver cirrhosis (LC) were remarkably lower than those of the normal subjects. The result suggests that HDL3 may be produced in the liver. Both the serum HDL2-C and HDL3-C levels were significantly lower in the patients with coronary heart disease (CHD) or cerebral thrombosis (CT) than in the normal subjects (P less than 0.001). In the normal subjects, the changes in the serum HDL-cholesterol (HDL-C) levels were mainly due to those in the serum HDL2-C levels. On the other hand, in the patients with atherosclerotic diseases (CHD, or CT) the changes in the serum HDL-C levels Were attributed to those of both the serum HDL2-C and HDL3-C levels. So it is suggested that in the atherosclerotic diseases, in which the HCL-C is usually lower, the HDL3-C also may play an important role in the regulation of the total HDL-C and its anti-atherogenetic effect.
 ...
PMID:Role and metabolism of high density lipoprotein subfractions--analysis of serum HDL2-cholesterol and HDL3-cholesterol in patients with various diseases by high performance liquid chromatography. 695 38

We determine the concentration of proapolipoprotein (proapo) A-I and its ratio with total apolipoprotein (apo) A-I (proapo A-I/total apo A-I) in plasma of patients with liver disease; we used a noncompetitive sandwich method, an enzyme-linked immunosorbent assay. The mean (SD) proapo A-I concentrations in patients with decompensated or compensated liver cirrhosis were higher than in normal subjects: 88 (25), 105 (36), and 69 (25) mg/L, respectively. The mean (SD) ratio (expressed as %) for each of these types of liver cirrhosis was also higher than in normal subjects: 10.0 (3.5), 10.2 (3.9), and 4.6 (1.6), respectively. In the patients, the proapo A-I concentration was positively correlated with the concentration of high-density lipoprotein subtype 2 cholesterol (HDL2-C) (r = 0.736), and the proapo A-I/total apo A-I ratio was correlated inversely with the HDL3-C concentration (r = -0.609). The activity of proapo A-I converting enzyme in patients with liver cirrhosis (62 +/- 30 nmol/h per liter) was significantly (P < 0.01) lower than that in normal subjects (172 +/- 55 nmol/h per liter). The increases of the plasma proapo A-I concentration and ratio in patients with liver cirrhosis may be caused by a decreased production of the converting enzyme in the liver. The increase of plasma proapo A-I may thus also affect the circulating HDL subtypes.
 ...
PMID:Increase of plasma proapolipoprotein A-I in patients with liver cirrhosis and its relationship to circulating high-density lipoproteins 2 and 3. 841 59